- Company
- Changes in sales and marketing of companies
- by Moon, sung-ho Feb 15, 2022 05:53am
- As the COVID-19 pandemic continues for more than three years, changes are also taking place in academic sales and marketing of pharmaceutical companies. Pharmaceutical companies are competitively holding events for doctors on a rich theme and scale comparable to academic conferences of medical associations. This is a self-rescue measure due to t
- Company
- The era of personalized healthcare has arrived
- by Eo, Yun-Ho Feb 14, 2022 05:54am
- Optimal treatment for each patient differs by one’s genetic mutation. With this discovery, anticancer therapies targeting individualized genes have emerged one after another, and the field of precision medicine is evolving from ‘disease-targeted’ to ‘gene-targeted’ prescriptions. In particular, anticipation in the field is rising wit
- Company
- Saxenda is also effective for childhood obesity
- by Feb 14, 2022 05:54am
- Saxenda of Novonodisc, a drug that can be used in children and adolescents, has emerged as an option for the first time. Effective weight loss is expected to help treat obesity in children and adolescents, but the fact that there is little data on Koreans should be supplemented. Novonodisc held a " Saxenda expansion of Pediatric Adaptation
- Company
- Successful renewal of RSA contract for Keytruda
- by Eo, Yun-Ho Feb 11, 2022 05:56am
- Keytruda, an immuno-cancer drug, succeeded in renewing its RSA contract for the first time in half a year. According to related industries, MSD Korea signed an RSA renewal with the NHIS last month for indications such as NSCLC therapy, which is currently covered by PD-1 low-release Keytruda. Keytruda, which contract expired in August la
- Company
- Prodrug for Forxiga patent dispute ruling has been postponed
- by Kim, Jin-Gu Feb 11, 2022 05:55am
- The second trial ruling on the patent dispute between Dong-A ST and AstraZeneca over Forxiga, a diabetes treatment based on SGLT-2 inhibitors, has been postponed. The Patent Court's 5-2 Court postponed the date of the judgment on the trial decision cancellation suit filed by AstraZeneca against Dong-A ST from the 10th to the 17th. The cour
- Company
- Skyrizi adds psoriatic arthritis indication
- by Feb 10, 2022 05:54am
- Abbvie’s ‘Skyrizi’ has expanded its indication to psoriatic arthritis. As the fourth interleukin inhibitor to receive approval for the indication, Skyrizi has set out to overtake the market with its convenience in administration. On the 9th, Abbvie Korea has held a ‘Press Conference to celebrate Skyrizi’s indication expansion to psor
- Company
- SK Bioscience releases second batch of COVID-19 vaccines
- by Kim, Jin-Gu Feb 10, 2022 05:54am
- SK Bioscience announced that it had shipped its second batch of commercial COVID-19 vaccine products. By manufacturing vaccines for AstraZeneca and then Novavax, the industry's evaluation is that the company has well demonstrated its large-scale and stable manufacturing capacity. SK Bioscience announced that it had shipped the first batch
- Company
- Effect of the release of generics for Tamsulosin
- by Ji Yong Jun Feb 10, 2022 05:54am
- The size of the Tamsulosin market, a treatment for prostatic hypertrophy, has soared. The market is also expanding as the influence of generic products has increased since the patent expired in 2015. According to UBIST, a pharmaceutical market research firm, on the 5th, Tamsulosin's outpatient prescription amount last year was 191.2 billion w
- Company
- Sales in the PPI market are↑ 60% over the past 3 years
- by Kim, Jin-Gu Feb 10, 2022 05:53am
- The PPI anti- ulcer drug market has changed rapidly since the Ranitidine crisis. The market expanded sharply shortly after Ranitidine crisis, but growth has slowed down in the past year. Esomeprazole, Rabeprazole, and Ilaprazole enjoyed the reflective effect of Ranitidine crisis. On the other hand, in the case of Lansoprazole and Pantoprazole
- Company
- Opdivo to be deliberated by CDDC for stomach cancer indicati
- by Eo, Yun-Ho Feb 9, 2022 06:10am
- Whether a reimbursed treatment option would become available in the field of gastric cancer is receiving attention. According to industry sources, Ono and BMS’s PD-1 inhibitor immuno-oncology drug ‘Opdivo (nivolumab)’ will be deliberated by the National Health Insurance Service’s Cancer Disease Deliberation Committee on the 23rd of
